Olesoxime protects against cisplatin-induced acute kidney injury by attenuating mitochondrial dysfunction.

ABSTRACT:

Background

Mitochondrial dysfunction is a critical factor in the pathogenesis of acute kidney injury (AKI). Agents that ameliorate mitochondrial dysfunction hold potential for AKI treatment. The objective of this study was to investigate the impact of olesoxime, a novel mitochondrial-targeted agent, on cisplatin-induced AKI.

Methods

In vivo, a cisplatin-induced AKI mouse model was established by administering a single intraperitoneal dose of cisplatin (25 mg/kg) to male C57BL/6 mice for 72 hours, followed by gavage of either olesoxime or a control solution. In vitro, human proximal tubular HK2 cells were cultured and subjected to treatments with cisplatin, either in the presence or absence of olesoxime.

Results

In vivo, our findings demonstrated that olesoxime adminis

SUBMITTER: Wang P 

PROVIDER: S-EPMC11751417 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature